Granules India Limited (BOM:532482)
573.95
-7.65 (-1.32%)
At close: Jan 19, 2026
Granules India Revenue
Granules India had revenue of 12.97B INR in the quarter ending September 30, 2025, with 34.18% growth. This brings the company's revenue in the last twelve months to 48.42B, up 8.14% year-over-year. In the fiscal year ending March 31, 2025, Granules India had annual revenue of 44.82B, down -0.55%.
Revenue (ttm)
48.42B
Revenue Growth
+8.14%
P/S Ratio
2.83
Revenue / Employee
11.91M
Employees
4,066
Market Cap
137.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
| Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
| Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
| Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
| Mar 31, 2021 | 32.38B | 6.39B | 24.59% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 76.18B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| GlaxoSmithKline Pharmaceuticals | 37.09B |
| FDC Limited | 20.77B |
| Caplin Point Laboratories | 20.42B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |
| Viyash Scientific | 16.58B |
Granules India News
- 1 day ago - Pharma sector stocks rally today: Dr. Reddy’s Laboratories up 5%, Granules India jumps 4.33%, Strides Pharma jumps 4% - Business Upturn
- 15 days ago - Granules India subsidiary gets FDA tentative approval for generic DYANAVEL XR tablets - Business Upturn
- 4 weeks ago - Granules India board approves fundraise of upto Rs 1,462 crore via issue of warrants at Rs 585 - Business Upturn
- 4 weeks ago - Granules India subsidiary receives FDA Tentative Approval for Generic Amphetamine Extended-Release Orally Disintegrating Tablets - Business Upturn
- 5 weeks ago - Granules India subsidiary completes USFDA inspection with five procedural observations - Business Upturn
- 5 weeks ago - Granules India subsidiary receives five procedural observations after US FDA GMP inspection - Business Upturn
- 6 weeks ago - Granules India subsidiary secures FDA EIR for Hyderabad Facility - Business Upturn
- 7 weeks ago - Granules packaging unit clears USFDA inspection - The Times of India